Johnson & Johnson expects to achieve above-market compound annual growth in its pharmaceuticals business between 2019 and 2023, including from current and future growth drivers. The company highlighted its pharma portfolio in a six-hour analyst meeting at its headquarters in New Brunswick, NJ, on 15 May, the first such overview in two years.
Similar to the last meeting in May 2017, management provided investors with an update on blockbuster medicines already in the portfolio and targeted regulatory filing dates for new medicines
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?